Moleculin Biotech (MBRX) Cash & Equivalents (2015 - 2026)
Moleculin Biotech (MBRX) posted Cash & Equivalents of $7.26 million for Q2 2026, down 3.9% from $7.56 million a year earlier.
Powered by 
Analysis
Moleculin Biotech (MBRX) Cash & Equivalents (2015 - 2026) Analysis & Trends
At the end of FY2025, Moleculin Biotech's Cash & Equivalents came in at $8.88 million, up 107.5% from FY2024.
- Annual Cash & Equivalents shows a five-year compound annual growth rate of -10.2% (FY2020 to FY2025).
- In prior years, Moleculin Biotech's Cash & Equivalents was $4.28 million in FY2024 (-81.8%), $23.55 million in FY2023 (-45.4%), $43.15 million in FY2022 (-39.1%) and $70.9 million in FY2021 (+367.3%).
- Quarterly Cash & Equivalents has run from a low of $4.28 million in Q4 2024 to a high of $75.2 million in Q3 2021 over five years.
- On a year-over-year basis, Cash & Equivalents increased in 1 of the last seven quarters, with an average decline of 21.9%.
- The strongest year-over-year quarter for Cash & Equivalents in the past five years was Q3 2021, with growth of 487.7%; the weakest was Q4 2024, with a decline of 81.8%.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,082.65 Bn | 1,051.23 Bn | 19.71 Bn | 8.95 Bn |
| 2 | Johnson & Johnson | 623.68 Bn | 542.21 Bn | 17.26 Bn | 20.42 Bn |
| 3 | AbbVie | 459.43 Bn | 432.59 Bn | 12.70 Bn | 6.57 Bn |
| 4 | Merck | 354.80 Bn | 309.23 Bn | 12.21 Bn | 6.85 Bn |
| 5 | Novartis Ag | 269.16 Bn | 225.03 Bn | 11.24 Bn | 7.62 Bn |
| 6 | Astrazeneca | 244.40 Bn | 217.97 Bn | 12.86 Bn | 4.89 Bn |
| 7 | Amgen | 220.17 Bn | 175.57 Bn | 7.24 Bn | 13.99 Bn |
| 8 | Gilead Sciences | 183.05 Bn | 157.16 Bn | 6.22 Bn | 3.18 Bn |
| 9 | Pfizer | 160.27 Bn | 107.22 Bn | 10.94 Bn | 976.00 Mn |
| 10 | Moleculin Biotech | 2.84 Mn | 2.84 Mn | - | 7.26 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 7.26 Mn |
| Dec 31, 2025 | 8.88 Mn |
| Sep 30, 2025 | 6.70 Mn |
| Jun 30, 2025 | 7.56 Mn |
| Mar 31, 2025 | 7.72 Mn |
| Dec 31, 2024 | 4.28 Mn |
| Sep 30, 2024 | 9.41 Mn |
| Jun 30, 2024 | 10.85 Mn |
| Mar 31, 2024 | 16.82 Mn |
| Dec 31, 2023 | 23.55 Mn |
| Sep 30, 2023 | 24.60 Mn |
| Jun 30, 2023 | 32.20 Mn |
| Mar 31, 2023 | 37.30 Mn |
| Dec 31, 2022 | 43.15 Mn |
| Sep 30, 2022 | 50.40 Mn |
| Jun 30, 2022 | 58.00 Mn |
| Mar 31, 2022 | 66.10 Mn |
| Dec 31, 2021 | 70.90 Mn |
| Sep 30, 2021 | 75.20 Mn |
| Jun 30, 2021 | 79.51 Mn |
API Access
Moleculin Biotech Cash & Equivalents API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=MBRX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "cash-and-equivalents", "ticker": "MBRX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=MBRX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();